Stockreport

SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations

SAB Biotherapeutics, Inc.  (SABS) 
PDF SIOUX FALLS, S.D., May 19, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform [Read more]